Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Multi gene mutation signatures in colorectal cancer patients: predict for the diagnosis, pathological classification, staging and prognosis

Open access

Abstract

Background: Identifying gene mutation signatures will enable a better understanding for the occurrence and development of colorectal cancer (CRC), and provide some potential biomarkers for clinical practice. Currently, however, there is still few effective biomarkers for early diagnosis and prognostic judgment in CRC patients. The purpose was to identify novel mutation signatures for the diagnosis and prognosis of CRC. Methods: Clinical information of 531 CRC patients and their sequencing data were downloaded from TCGA database (training group), and 53 clinical patients were collected and sequenced with targeted next generation sequencing (NGS) technology (validation group). The relationship between the mutation genes and the diagnosis, pathological type, stage and prognosis of CRC were compared to construct signatures for CRC, and then analyzed their relationship with RNA expression, immunocyte infiltration and tumor microenvironment (TME). Results: Mutations of TP53, APC, KRAS, BRAF and ATM covered 97.55% of TCGA population and 83.02% validation patients. Moreover, 57.14% validation samples and 22.06% TCGA samples indicated that patients with mucinous adenocarcinoma tended to have BRAF mutation, but no TP53 mutation. Mutations of TP53, PIK3CA, FAT4, FMN2 and TRRAP had a remarkable difference between I-II and III-IV stage patients (P < 0.0001). Besides, the combination of PIK3CA, LRP1B, FAT4 and ROS1 formed signatures for the prognosis and survival of CRC patients. The mutations of TP53, APC, KRAS, BRAF, ATM, PIK3CA, FAT4, FMN2, TRRAP, LRP1B, and ROS1 formed the signatures for predicting diagnosis and prognosis of CRC. Among them, mutation of TP53, APC, KRAS, BRAF, ATM, PIK3CA, FAT4 and TRRAP significantly reduced their RNA expression level. Stromal score, immune score and ESTIMATE score were lower in patients with TP53, APC, KRAS, PIK3CA mutation compared non-mutation patients. All the 11 gene mutations affected the distributions of immune cells. Conclusion: This study constructed gene mutation signatures for the diagnosis, treatment and prognosis in CRC, and proved that their mutations affected RNA expression levels, TME and immunocyte infiltration. Our results put forward further insights into the genotype of CRC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12885-021-08108-9

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 The clinical characteristics and gene mutation landscape in TCGA and validation samples. There are 44 mutation genes occurred and the mutation frequencies were more than 5% both in TCGA and validation samples. a clinical information (left) and the mutation frequencies of the 44 genes (right) in TCGA samples; b clinical information and the mutation frequencies of the 44 genes in validation samples; c the distribution of genes on the pathways over 30 scores in GeneCards
Fig. 1 The clinical characteristics and gene mutation landscape in TCGA and validation samples. There are 44 mutation genes occurred and the mutation frequencies were more than 5% both in TCGA and validation samples. a clinical information (left) and the mutation frequencies of the 44 genes (right) in TCGA samples; b clinical information and the mutation frequencies of the 44 genes in validation samples; c the distribution of genes on the pathways over 30 scores in GeneCardsCC BY · PubMed Central
Fig. 2 The mutated gene signature for the diagnosis of colorectal cancer. Mutations of TP53, APC, KRAS, BRAF and ATM covering 97.55% of TCGA population and 84.9% validation patients, and they can be used to distinguish between cancer and paracancer. a The mutation distribution of TP53, APC, KRAS, BRAF and ATM inTCGA and validation patients. Different colors represented different mutation types, and red represented frame-shift mutation, yellow in-frame mutation, green missense mutation, blue nonsense mutation and black splice site mutation; b The Venn diagram of mutations of TP53, APC, KRAS, BRAF and ATM in TCGA population; c The Venn diagram of mutations of TP53, APC, KRAS, BRAF and ATM in validation population
Fig. 2 The mutated gene signature for the diagnosis of colorectal cancer. Mutations of TP53, APC, KRAS, BRAF and ATM covering 97.55% of TCGA population and 84.9% validation patients, and they can be used to distinguish between cancer and paracancer. a The mutation distribution of TP53, APC, KRAS, BRAF and ATM inTCGA and validation patients. Different colors represented different mutation types, and red represented frame-shift mutation, yellow in-frame mutation, green missense mutation, blue nonsense mutation and black splice site mutation; b The Venn diagram of mutations of TP53, APC, KRAS, BRAF and ATM in TCGA population; c The Venn diagram of mutations of TP53, APC, KRAS, BRAF and ATM in validation populationCC BY · PubMed Central
Fig. 3 Mutations of TP53 and BRAF were association with clinicopathological characteristics (mucinous adenocarcinoma and other adenocarcinoma). “TP53, BRAF:+,-” indicated TP53 mutated, but BRAF not; “TP53, BRAF:+,+” indicated both TP53 and BRAF mutated; “TP53, BRAF:-,+” indicated BRAF mutated, but TP53 not; “TP53, BRAF:-,-” indicated both TP53 and BRAF not mutated. a In TCGA samples, “TP53, BRAF:+,+”, “TP53, BRAF:-,+” and “TP53, BRAF:-,-” were more likely to occur in mucinous adenocarcinoma patients (red) than other adenocarcinoma patients (blue). P represents the significance of the overall difference between the four groups. b In validation samples, more than 50% mucinous adenocarcinoma patients were “TP53, BRAF:-,+”, while none of them were other adenocarcinoma. P represents the significance of the overall difference between the four groups. c The circular map and data chart of TP53 and BRAF mutation percentages in different pathological types. The outer to inner ring represents the mucinous adenocarcinoma in the validation group, other adenocarcinoma in the validation group, mucinous adenocarcinoma in the TCGA group, and other adenocarcinoma in the TCGA group
Fig. 3 Mutations of TP53 and BRAF were association with clinicopathological characteristics (mucinous adenocarcinoma and other adenocarcinoma). “TP53, BRAF:+,-” indicated TP53 mutated, but BRAF not; “TP53, BRAF:+,+” indicated both TP53 and BRAF mutated; “TP53, BRAF:-,+” indicated BRAF mutated, but TP53 not; “TP53, BRAF:-,-” indicated both TP53 and BRAF not mutated. a In TCGA samples, “TP53, BRAF:+,+”, “TP53, BRAF:-,+” and “TP53, BRAF:-,-” were more likely to occur in mucinous adenocarcinoma patients (red) than other adenocarcinoma patients (blue). P represents the significance of the overall difference between the four groups. b In validation samples, more than 50% mucinous adenocarcinoma patients were “TP53, BRAF:-,+”, while none of them were other adenocarcinoma. P represents the significance of the overall difference between the four groups. c The circular map and data chart of TP53 and BRAF mutation percentages in different pathological types. The outer to inner ring represents the mucinous adenocarcinoma in the validation group, other adenocarcinoma in the validation group, mucinous adenocarcinoma in the TCGA group, and other adenocarcinoma in the TCGA groupCC BY · PubMed Central
Fig. 4 The mutated gene signature for the stage of colorectal cancer. Mutations of TP53, PIK3CA, FAT4, FMN2 and TRRAP had a remarkable difference between I-II and III-IV stage patients (P < 0.0001). a The distribution of the 5 mutated genes in different stages of TCGA samples. The figures above and below were stage I-II group and stage III-IV group, respectively. Each bar represents a patient. b The gene mutation frequencies of TP53, PIK3CA, FAT4, FMN2 and TRRAP in validation (left) and TCGA (right) samples
Fig. 4 The mutated gene signature for the stage of colorectal cancer. Mutations of TP53, PIK3CA, FAT4, FMN2 and TRRAP had a remarkable difference between I-II and III-IV stage patients (P < 0.0001). a The distribution of the 5 mutated genes in different stages of TCGA samples. The figures above and below were stage I-II group and stage III-IV group, respectively. Each bar represents a patient. b The gene mutation frequencies of TP53, PIK3CA, FAT4, FMN2 and TRRAP in validation (left) and TCGA (right) samplesCC BY · PubMed Central
Fig. 5 The mutated gene signature for the prognosis of colorectal cancer. PIK3CA, LRP1B, FAT4 and ROS1 were significantly correlated with overall survival (P < 0.001). a In TCGA samples, the distribution of the 4 mutated genes in patients with different OS. The figures from top to bottom were OS < 1 year group, 1 < OS < 3 years group, and OS > 3 years group in sequence. b In validation samples, mutation survival curve of LRP1B (left) and FAT4 (right) genes
Fig. 5 The mutated gene signature for the prognosis of colorectal cancer. PIK3CA, LRP1B, FAT4 and ROS1 were significantly correlated with overall survival (P < 0.001). a In TCGA samples, the distribution of the 4 mutated genes in patients with different OS. The figures from top to bottom were OS < 1 year group, 1 < OS < 3 years group, and OS > 3 years group in sequence. b In validation samples, mutation survival curve of LRP1B (left) and FAT4 (right) genesCC BY · PubMed Central
Fig. 6 The relationship between gene mutation and its RNA expression level in TCGA cohort. Mutations of TP53, APC, KRAS, BRAF, ATM, PIK3CA, FAT4, and TRRAP significantly down-regulated their RNA expression levels (P < 0.001). a-k Comparison of RNA expression levels between mutation and non-mutation gene of TP53 (a), APC (b), KRAS (c), BRAF (d), ATM (E), PIK3CA (f), FAT4 (g), FMN2 (h), TRRAP (i), LRP1B (j) and ROS1 (k) in CRC patients
Fig. 6 The relationship between gene mutation and its RNA expression level in TCGA cohort. Mutations of TP53, APC, KRAS, BRAF, ATM, PIK3CA, FAT4, and TRRAP significantly down-regulated their RNA expression levels (P < 0.001). a-k Comparison of RNA expression levels between mutation and non-mutation gene of TP53 (a), APC (b), KRAS (c), BRAF (d), ATM (E), PIK3CA (f), FAT4 (g), FMN2 (h), TRRAP (i), LRP1B (j) and ROS1 (k) in CRC patientsCC BY · PubMed Central
Fig. 7 Relationship between immunocyte infiltration and gene mutation status in the mutated gene signatures. Activated CD4 T cell and T-follicular helper cell had significant differences in all genes between mutated and non-mutated status (P < 0.05), while the distribution of CD56dim natural killer cell, monocyte and eosinophil were different in less genes. a-k Comparison of distribution of immune cells between mutation and non-mutation gene of TP53 (a), APC (b), KRAS (c), BRAF (d), ATM (e), PIK3CA (f), FAT4 (g), FMN2 (h), TRRAP (i), LRP1B (j), and ROS1 (k) in CRC patients
Fig. 7 Relationship between immunocyte infiltration and gene mutation status in the mutated gene signatures. Activated CD4 T cell and T-follicular helper cell had significant differences in all genes between mutated and non-mutated status (P < 0.05), while the distribution of CD56dim natural killer cell, monocyte and eosinophil were different in less genes. a-k Comparison of distribution of immune cells between mutation and non-mutation gene of TP53 (a), APC (b), KRAS (c), BRAF (d), ATM (e), PIK3CA (f), FAT4 (g), FMN2 (h), TRRAP (i), LRP1B (j), and ROS1 (k) in CRC patientsCC BY · PubMed Central
Fig. 8 The relationship between tumor microenvironment (TME) and gene mutation status in the mutated gene signatures. Patients with mutant TP53, APC, KRAS, PIK3CA had lower stromal score, immune score, ESTIMATE core and higher tumor purity compared with non-mutated patients, and the TME in patients with BRAF, ATM, LRP1B, FAT4, FMN2, TRRAP, and ROS1 mutations showed the opposite trend. a Comparison of stromal score between mutated and non-mutated patients. b Comparison of immune score between mutated and non-mutated patients. c Comparison of ESTIMATE score between mutated and non-mutated patients. d Comparison of tumor purity between mutated and non-mutated patients
Fig. 8 The relationship between tumor microenvironment (TME) and gene mutation status in the mutated gene signatures. Patients with mutant TP53, APC, KRAS, PIK3CA had lower stromal score, immune score, ESTIMATE core and higher tumor purity compared with non-mutated patients, and the TME in patients with BRAF, ATM, LRP1B, FAT4, FMN2, TRRAP, and ROS1 mutations showed the opposite trend. a Comparison of stromal score between mutated and non-mutated patients. b Comparison of immune score between mutated and non-mutated patients. c Comparison of ESTIMATE score between mutated and non-mutated patients. d Comparison of tumor purity between mutated and non-mutated patientsCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 44 references

Cited by

See all 54

Metadata

Authors
Zhuang, Y., Wang, H., Jiang, D., Li, Y., Feng, L., Tian, C., Pu, M., Wang, X., Zhang, J., Hu, Y., & Liu, P.
Affiliations
  • Tianjin Medical University Cancer Institute and Hospital (CN)
  • Fourth Hospital of Hebei Medical University (CN)
  • Tianjin Central Hospital of Gynecology Obstetrics (CN)
Corresponding author
  • Hu, Yuanjing
  • Liu, Pengfei
Venue
BMC Cancer
Published
2021-04-09
Volume
21
Issue
1
Pages
380-380
ISSN
1471-2407 (ISSN-L)
OpenAlex
W3145382638
Cited by
54
References
44
Citations by year
2026: 5 · 2025: 13 · 2024: 14 · 2023: 14 · 2022: 4 · 2021: 4
FWCI
6.00
Type
journal article
Language
en
Open access
Licence
Locations
  • BMC Cancer (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Tianjin Science and Technology Plan Project (17ZXMFSY00160)
Topics
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords
colorectal cancer, TP53 mutation, APC mutation, KRAS mutation, BRAF mutation, ATM mutations, PIK3CA mutation, ROS1 mutation, prognostic factors, diagnostic biomarkers, tumor microenvironment, immune cell infiltration, stromal score, immune score, tumor stage, mucinous adenocarcinoma, gene expression
MeSH terms
Adult, Aged, Alleles, Female, Genotype, Humans, Male, Middle Aged, Mutation, Neoplasm Staging, Prognosis, Proto-Oncogene Proteins, Biomarkers, Tumor, Colorectal Neoplasms, Survival Analysis, Computational Biology, Tumor Suppressor Proteins, Genetic Association Studies, High-Throughput Nucleotide Sequencing, Tumor Microenvironment, Neoplasm Grading

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Multi gene mutation signatures in colorectal cancer patients: predict for the diagnosis, pathological classification, staging and prognosis. https://app.cochat.ai/papers/10.1186/s12885-021-08108-9
The paper
Zhuang, Y., Wang, H., Jiang, D., Li, Y., Feng, L., Tian, C., Pu, M., Wang, X., Zhang, J., Hu, Y., & Liu, P. (2021). Multi gene mutation signatures in colorectal cancer patients: predict for the diagnosis, pathological classification, staging and prognosis. BMC Cancer. https://doi.org/10.1186/s12885-021-08108-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.